US regulators to review controversial peptides backed by RFK Jr. despite lack of evidence

The US Food and Drug Administration is set to weigh the regulatory status of peptide compounds whose popularity has surged amid promotion by Health Secretary RFK Jr. The compounds are marketed for sleep improvement, muscle growth and anti-ageing, but the FDA has questioned the scientific evidence behind such claims. Demand for the substances has grown sharply in recent months.